TNFR2 agonism increases tissue and effector Treg cells
The Journal of Immunology · 02.11.2026 · 215 (11)
DOI: 10.1093/jimmun/vkag291 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 10.11.2026. Verfasst von Delia Mihaela Mihoc und 29 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Immunology, University Medical Center Mainz, Mainz, Germany. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Receptors, Tumor Necrosis Factor, Type II, Encephalomyelitis, Autoimmune, Experimental. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, DFG, German Research Foundation.
Abstract (Originalsprache)
Autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus (SLE) are driven by chronic inflammation and tissue damage. Regulatory T (Treg) cells are critical for maintaining immune tolerance, yet their therapeutic use is limited by stability and tissue homing. Here, we demonstrate that agonism of tumor necrosis factor receptor 2 (TNFR2) increases effector and tissue-competent Treg cell progenitors in mice and humans. Single-cell RNA sequencing reveals that TNFR2 is highly expressed on early and late nonlymphoid tissue Treg cell precursors, with expression strongly correlated with the BATF-driven tissue Treg cell transcriptional program. In vivo, a single dose of TNFR2 agonist promotes the clonal commitment of Treg cells to effector and tissue lineage, increasing tissue Treg cell populations in lymphoid and peripheral tissues. This increase is associated with enhanced suppressive function, epigenetic stability (preserved FOXP3 CNS2 demethylation), and resistance to inflammatory conversion. In murine models of skin inflammation and experimental autoimmune encephalomyelitis, TNFR2 agonism ameliorates disease severity in a dose-dependent manner. Critically, in human Treg cells, TNFR2 agonism induces elements of the tissue residency transcriptional program—including upregulation of LAYN, CCR8, CCR4, and TIGIT—while maintaining lineage stability. These findings establish TNFR2 signaling as a central driver of effector and tissue Treg cell differentiation and position TNFR2 agonism as a transformative strategy for generating stable, tissue-competent effector Treg cells as a promising immunomodulatory therapy for autoimmune and inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Immunology, University Medical Center Mainz, Mainz, Germany.
- Research Center for Immunotherapy, University Medical Center Mainz, Mainz, Germany.
- Odyssey Therapeutics Inc, Boston, MA, United States.
- Institute of Computational Biology, Helmholtz Munich, Munich, Germany.
- High Performance Computing and Data Center, University of Mainz, Mainz, Germany.
- Department of Dermatology, University Medical Center Mainz, Mainz, Germany.
ORCID-Profile: Michael Delacher
Förderung
- Deutsche Forschungsgemeinschaft
- DFG
- German Research Foundation
Zitieren
APA
Mihoc, D. M., McMillan, E., Swee, L. K., Helbich, S. S., Knopf, J. D., Próchnicki, T., Singhal, R., Sanchez, B., Telling, A., Huber, F., Beumer, N., Singh, K., Kaufmann, T., Voss, M. M., Braband, K. L., Weihberg, A., Lu, H., Stuwe, T., Soisson, S. M., …, & Delacher, M. (2026). TNFR2 agonism increases tissue and effector Treg cells. The Journal of Immunology, 215(11). https://doi.org/10.1093/jimmun/vkag291
Vancouver
Mihoc DM, McMillan E, Swee LK, Helbich SS, Knopf JD, Próchnicki T, et al. TNFR2 agonism increases tissue and effector Treg cells. The Journal of Immunology. 2026;215(11). doi:10.1093/jimmun/vkag291
BibTeX
@article{Mihoc2026,
author = {Mihoc, Delia Mihaela and McMillan, Elizabeth and Swee, Lee Kim and Helbich, Sara Salome and Knopf, Julia Daniela and Próchnicki, Tomasz and Singhal, Rashi and Sanchez, Brian and Telling, Alissa and Huber, Ferdinand and Beumer, Niklas and Singh, Kartikeya and Kaufmann, Tamara and Voss, Morten Michael and Braband, Kathrin Luise and Weihberg, Andrea and Lu, Hanbin and Stuwe, Tobias and Soisson, Stephen M and Aardalen, Kimberly and Landry, Casey and O'Donnell, Taylor and Henkel, Andreas and Wittmann, Miriam and Kramer, Daniela and Bopp, Tobias and Schild, Hansjoerg and Pinheiro, Elaine Maria and Franchi, Luigi and Delacher, Michael},
title = {TNFR2 agonism increases tissue and effector Treg cells},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {11},
doi = {10.1093/jimmun/vkag291}
}
EUVIMED